Inmaculada Hernandez-Lopez

Madrid, MD, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 41 publications

Comparative analysis of disk diffusion and microscan versus broth microdilution methods for determining antimicrobial susceptibility of cefepime and piperacillin-tazobactam in Escherichia coli isolates carrying blaOXA-1.

Comparative analysis of disk diffusion and microscan versus broth microdilution methods for determining antimicrobial susceptibility of cefepime and piperacillin-tazobactam in Escherichia coli isolates carrying blaOXA-1.

Journal: Antimicrobial agents and chemotherapy

Published: June 27, 2026

Comparative activity of ceftibuten combinations with avibactam, ledaborbactam, and xeruborbactam against recombinant β-lactamase-producing Escherichia coli and contemporary WGS-characterized strains of carbapenemase-producing Enterobacterales.

Comparative activity of ceftibuten combinations with avibactam, ledaborbactam, and xeruborbactam against recombinant β-lactamase-producing Escherichia coli and contemporary WGS-characterized strains of carbapenemase-producing Enterobacterales.

Journal: Antimicrobial agents and chemotherapy

Published: May 29, 2026

Evaluation of a novel lateral flow immunochromatographic assay, Certest ResisCheck® Carbapenemases, for the rapid detection and differentiation of carbapenemase in Gram-negative bacteria from bacterial culture.

Evaluation of a novel lateral flow immunochromatographic assay, Certest ResisCheck® Carbapenemases, for the rapid detection and differentiation of carbapenemase in Gram-negative bacteria from bacterial culture.

Journal: The Journal of antimicrobial chemotherapy

Published: January 12, 2026

Mortality risk of ESBL producers in Escherichia coli bacteraemia: a comprehensive analysis using the PROBAC cohort.

Mortality risk of ESBL producers in Escherichia coli bacteraemia: a comprehensive analysis using the PROBAC cohort.

Journal: The Journal of antimicrobial chemotherapy

Published: December 01, 2025

External validation of the predictive ability of Charson, SOFA, Pitt, INCREMENT-ESBL and bloodstream infection mortality Risk for 30-day-mortality in bacteraemia using the PROBAC cohort data.

External validation of the predictive ability of Charson, SOFA, Pitt, INCREMENT-ESBL and bloodstream infection mortality Risk for 30-day-mortality in bacteraemia using the PROBAC cohort data.

Journal: Infectious diseases (London, England)

Published: July 09, 2025

A matched case-control study on Escherichia coli factors contributing to sepsis and septic shock in bacteraemic patients.

A matched case-control study on Escherichia coli factors contributing to sepsis and septic shock in bacteraemic patients.

Journal: Communications medicine

Published: June 24, 2025

Development and validation of a predictive mortality scoring model for bloodstream infections due to Escherichia coli in the PROBAC cohort.

Development and validation of a predictive mortality scoring model for bloodstream infections due to Escherichia coli in the PROBAC cohort.

Journal: Infection

Published: April 23, 2025

Fosfomycin in bacteraemic urinary tract infection due to multidrug-resistant Escherichia coli: insights of post hoc DOOR analysis of the FOREST trial.

Fosfomycin in bacteraemic urinary tract infection due to multidrug-resistant Escherichia coli: insights of post hoc DOOR analysis of the FOREST trial.

Journal: Infectious diseases (London, England)

Published: December 09, 2024

Assessment of the activity and mechanisms of resistance to cefiderocol and combinations of β-lactams and the novel β-lactamase inhibitors avibactam, taniborbactam, zidebactam, nacubactam, xeruborbactam, and ANT3310 in emerging double-carbapenemase-producing Enterobacterales.

Assessment of the activity and mechanisms of resistance to cefiderocol and combinations of β-lactams and the novel β-lactamase inhibitors avibactam, taniborbactam, zidebactam, nacubactam, xeruborbactam, and ANT3310 in emerging double-carbapenemase-producing Enterobacterales.

Journal: Antimicrobial agents and chemotherapy

Published: October 09, 2024

Corrigendum to "Activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against isogenic strains of Escherichia coli expressing single and double β-lactamases under high and low permeability conditions" [International Journal of Antimicrobial Agents Volume 63, Issue 5 (2024) 107150].

Corrigendum to "Activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against isogenic strains of Escherichia coli expressing single and double β-lactamases under high and low permeability conditions" [International Journal of Antimicrobial Agents Volume 63, Issue 5 (2024) 107150].

Journal: International journal of antimicrobial agents

Published: July 09, 2024

Clinical characteristics, predisposing factors and outcomes for Enterococcus faecalis versus Enterococcus faecium bloodstream infections: a prospective multicentre cohort study.

Clinical characteristics, predisposing factors and outcomes for Enterococcus faecalis versus Enterococcus faecium bloodstream infections: a prospective multicentre cohort study.

Journal: European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology

Published: June 20, 2024

First characterization of a Klebsiella pneumoniae clinical isolate producing VEB-1 and OXA-436 in Spain.

First characterization of a Klebsiella pneumoniae clinical isolate producing VEB-1 and OXA-436 in Spain.

Journal: Enfermedades infecciosas y microbiologia clinica (English ed.)

Published: May 07, 2024

Showing 1-12 of 41

Last Updated: 09/26/2026